← ADMA BIOLOGICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $10.5m |
$15.6m
+48.48%
|
$17.0m
+8.76%
|
$29.3m
+72.79%
|
$42.2m
+43.85%
|
$80.9m
+91.72%
|
$154.1m
+90.36%
|
$258.2m
+67.59%
|
$426.5m
+65.15%
|
$510.2m
+19.63%
|
$512.3m
+0.41%
|
|
| Cost of Goods and Services Sold | $6.4m |
$2.8m
-56.34%
|
$42.2m
+1419.45%
|
$39.5m
-6.38%
|
$61.3m
+55.15%
|
$79.8m
+30.15%
|
$118.8m
+48.95%
|
$169.3m
+42.47%
|
$206.9m
+22.23%
|
$217.4m
+5.08%
|
$180.8m
-16.84%
|
|
| Gross Profit | $4.3m |
($6.4m)
-248.92%
|
($25.2m)
-293.66%
|
($10.2m)
+59.72%
|
($19.1m)
-87.80%
|
$1.2m
+106.15%
|
$35.3m
+2905.68%
|
$88.9m
+152.21%
|
$219.6m
+146.85%
|
$292.8m
+33.35%
|
$331.5m
+13.22%
|
|
| Research and Development Expense | $7.7m | $6.2m | $3.9m | $2.3m | $5.9m | $3.6m | $3.6m | $3.3m | $1.8m | $4.8m | $11.5m | |
| Marketing and Advertising Expense | — | $600k | $800k | $1.0m | $1.1m | $1.4m | $2.2m | $3.3m | $2.7m | $3.1m | — | |
| General and Administrative Expense | $8.5m | $18.1m | $22.5m | $25.9m | $35.1m | $42.9m | $52.5m | $59.0m | $74.1m | $91.6m | — | |
| Amortization of Intangible Assets | $0 | $1.2m | $845k | $845k | $715k | $715k | $715k | $724k | $388k | $144k | — | |
| Operating Lease, Expense | — | — | — | — | — | $1.4m | $2.1m | $2.4m | $2.4m | $2.4m | — | |
| Operating Expenses | $28.0m | $62.1m | $77.3m | $70.8m | $107.1m | $59.5m | $74.6m | $67.3m | $80.6m | $101.3m | $115.0m | |
| Other Operating Income | ($17.3m) | $7.0m | $0 | ($41.4m) | ($64.9m) | ($58.4m) | ($39.4m) | $21.6m | $139.0m | $191.4m | $216.5m | |
| Operating Income (Loss) | ($17.3m) |
($39.3m)
-126.83%
|
($60.3m)
-53.37%
|
($41.4m)
+31.29%
|
($64.9m)
-56.71%
|
($58.4m)
+10.08%
|
($39.4m)
+32.56%
|
$21.6m
+154.95%
|
$139.0m
+542.49%
|
$191.4m
+37.75%
|
$216.5m
+13.09%
|
|
| Interest Income, Other | $50k | $57k | $195k | $801k | — | — | — | — | — | — | $3.2m | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | $0 | — | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | — | ($10k) | ($127k) | ($227k) | ($129k) | ($252k) | ($634k) | ($287k) | ($193k) | ($212k) | — | |
| Interest Expense (non-operating) | $2.2m | $3.3m | $5.5m | $9.0m | $12.0m | $13.1m | $19.3m | $25.0m | $13.9m | $7.1m | $8.8m | |
| Other Expenses | — | — | — | $200k | — | — | — | — | — | — | — | |
| Other Income | $4k | — | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($19.5m) | — | — | — | — | — | $65.9m | $28.2m | $125.7m | $182.7m | $216.5m | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | — | $0 | $0 | $12.3m | $24.7m | $47.5m | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | ($72.0m) | $35.7m | $47.5m | |
| Net Income (Loss) Attributable to Parent | ($19.5m) |
($43.8m)
-124.23%
|
($65.7m)
-50.24%
|
($48.3m)
+26.56%
|
($75.7m)
-56.90%
|
($71.6m)
+5.41%
|
($65.9m)
+8.02%
|
($28.2m)
+57.15%
|
$197.7m
+800.00%
|
$146.9m
-25.67%
|
$169.0m
+14.99%
|
|
| Earnings Per Share, Basic | — | — | — | — | ($0.88) | ($0.51) | ($0.33) | ($0.13) | $0.85 | $0.62 | $0.72 | |
| Earnings Per Share, Diluted | ($1.61) | ($1.91) | ($1.45) | ($0.89) | ($0.88) | ($0.51) | ($0.33) | ($0.13) | $0.81 | $0.60 | $0.70 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 139.6m | 197.9m | 224.0m | 233.1m | 238.3m | 235.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 139.6m | 197.9m | 224.0m | 243.3m | 244.9m | 239.6m | |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related Costs | — | $3.9m | — | — | — | — | — | — | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | |
| Other Cost and Expense, Operating | $5.4m | $6.5m | $7.8m | $2.2m | $4.2m | $12.3m | $17.8m | $4.3m | $4.2m | $4.8m | — |